Skip to main content
SpringerLink
Log in

Mitiglinide

KAD 1229, S 21403

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Kissei Pharmaceutical Co Ltd, Takeda Chemical Industries Ltd. Announcement for Execution of Co-Marketing Agreement on ‘mitiglinide’, a blood glucose lowering agent. Media Release: 5 Aug 2002. Available from URL: http://www.kissei.co.jp

    Google Scholar 

  2. Recommendations for approval in Japan. Inpharma: 22, No. 1418, 20 Dec 2003

    Google Scholar 

  3. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treatments in Endocrinology 2: 401–414, No. 6, 2003

    Article  PubMed  CAS  Google Scholar 

  4. Yamada N, Shigeta Y, Kaneko T, et al. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM. Diabetes 45 (Suppl. 2): 74, May 1996

    Google Scholar 

  5. Mogami H, Shibata H, Nobusawa R. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. European Journal of Pharmacology — Molecular Pharmacology 269: 293–298, 15 Nov 1994

    Article  CAS  Google Scholar 

  6. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. European Journal of Pharma-cology 431: 119–125, 9 Nov 2001

    Article  CAS  Google Scholar 

  7. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and shortacting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal of Pharmacology 71: 315–323, Aug 1996

    Article  PubMed  CAS  Google Scholar 

  8. Komatsu H, Ohnota H, Koizumi T. Pharmacological profile of a rapid- and short-acting hypoglycemic agent KAD-1229, a non-sulfonylurea drug. Naunyn-Schmiedeberg’s Archives of Pharmacology 358 (Suppl. 1): 289, No. 1, 1998

    Google Scholar 

  9. Yamato T, Ichikawa K, Ojima K, et al. Effect of KAD-1229 on post-prandial hyperglycemia after oral meal load in STZ-induced diabetic rats. Japanese Journal of Pharmacology 85 (Suppl. I): 210, 2001

    Google Scholar 

  10. Ichikawa K, Yamato T, Ojima K, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clinical and Experimental Pharmacology and Physiology 29: 423–427, May–Jun 2002

    Article  PubMed  CAS  Google Scholar 

  11. Kusama H, Yamato T, Tsuji A, et al. Effect of KAD-1229 on postprandial hyperglycemia after oral meal load in STZ-in-duced diabetic rats. Pharmacologist 44 (Suppl. 1): 156–157, 2002

    Google Scholar 

  12. Misawa K, Ichikawa K, Ojima K, et al. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology 62: 65–72, No. 2, 2001

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitiglinide. Drugs R D 5, 98–101 (2004). https://doi.org/10.2165/00126839-200405020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200405020-00006

Keywords

Search

Navigation